David Liu (Rose Lincoln/Harvard Staff Photographer)
Out of CRISPR pioneer David Liu's lab comes a small molecule play targeting exosites — and it's raised a modest $25M to push toward clinic
David Liu may be best known as a CRISPR trailblazer behind Editas Medicine, Beam Therapeutics and Prime Medicine. But more than six years ago, he …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
